
Positive data from a pair of clinical trials announced at the 25th European Academy of Dermatology and Venereology Congress show Dupixent (dupilumab) is an effective option for moderate-to-severe atopic dermatitis.
Positive data from a pair of clinical trials announced at the 25th European Academy of Dermatology and Venereology Congress show Dupixent (dupilumab) is an effective option for moderate-to-severe atopic dermatitis.
Research presented at the 25th European Academy of Dermatology and Venereology Congress focused on the effects of crisaborole topical ointment in treating atopic dermatitis.
Results from clinical trials of Taltz presented at the European Academy of Dermatology and Venereology Congress.
New data for dupilumab presented at the 25th European Academy of Dermatology and Venereology Congress.
At the 25th European Academy of Dermatology and Venereology Congress in Vienna, Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health, discussed effective techniques to boost HIV drug adherence.
The promise of sentinel lymph node biopsies for melanoma highlighted at the 25th European Academy of Dermatology and Venereology Congress in Vienna, Austria.
Immune checkpoint inhibitors could improve malignant melanoma therapy, according to a study presented at the Congress of the European Academy of Dermatology and Venerology.
At the 25th European Academy of Dermatology and Venereology Congress in Vienna, Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health, discussed the importance of persistence in Truvada use for HIV pre-exposure prophylaxis.
AbbVie’s experimental compound treats moderate-to-severe chronic plaque psoriasis.
At the 25th European Academy of Dermatology and Venereology Congress in Vienna, Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health, discussed hurdles to proper drug adherence in HIV treatment.
Clinical trial presented at the 25th Annual European Academy of Dermatology and Venereology Congress found a new topical allantoin cream can help treat epidermolysis bullosa.
Stephen I. Katz, MD, PhD, director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, kicked off the European Academy of Dermatology and Venereology Congress highlighting the future of dermatology treatment.
Data presented at the European Academy of Dermatology and Venereology (EADV) Annual Congress shows safety and efficacy of apremilast (Otezla) over three years.
Aleksandar L. Krunic, MD, PhD, discusses tumor removal in Mohs disease during the 25th European Academy of Dermatology and Venereology Congress.
Aleksandar L. Krunic, MD, PhD, discusses treatment strategies for rare tumor types in Mohs disease during the 25th European Academy of Dermatology and Venereology Congress.